- Investing Ideas
- /
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
6
Companies with a Value score of at least 3, ordered by Value score
6 companies
H. Lundbeck
Market Cap: DKK 27.4b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 27.56
7D
-4.3%
1Y
-16.5%
Genmab
Market Cap: DKK 80.8b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,298.00
7D
0.4%
1Y
-35.4%
Bavarian Nordic
Market Cap: DKK 11.8b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 144.70
7D
-4.2%
1Y
-4.2%
Novo Nordisk
Market Cap: DKK 1.9t
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
NOVO B
DKK 390.00
7D
-8.4%
1Y
-56.2%
H. Lundbeck
Market Cap: DKK 26.5b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 23.45
7D
-4.7%
1Y
-17.0%
ALK-Abelló
Market Cap: DKK 32.9b
Operates as an allergy solutions company in Europe, North America, and internationally.
ALK B
DKK 144.10
7D
-1.7%
1Y
12.0%